207 related articles for article (PubMed ID: 28581634)
1. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection.
El Sherif O; Afhdal N; Curry M
J Viral Hepat; 2017 Oct; 24(10):808-813. PubMed ID: 28581634
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.
Molino S; Martin MT
Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743
[TBL] [Abstract][Full Text] [Related]
3. Changing the face of hepatitis C management - the design and development of sofosbuvir.
Noell BC; Besur SV; deLemos AS
Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
[TBL] [Abstract][Full Text] [Related]
4. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Bagaglio S; Uberti-Foppa C; Morsica G
Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
Bourlière M; Adhoute X; Ansaldi C; Oules V; Benali S; Portal I; Castellani P; Halfon P
Expert Rev Gastroenterol Hepatol; 2015; 9(12):1483-94. PubMed ID: 26595560
[TBL] [Abstract][Full Text] [Related]
6. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
7. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Wyles DL; Gutierrez JA
J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
[TBL] [Abstract][Full Text] [Related]
9. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
[TBL] [Abstract][Full Text] [Related]
11. Closing the Gap: The Challenges of Treating Hepatitis C Virus Genotype 3 Infection.
Martin MT; Deming P
Pharmacotherapy; 2017 Jun; 37(6):735-747. PubMed ID: 28374965
[TBL] [Abstract][Full Text] [Related]
12. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
Li DK; Chung RT
Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
[TBL] [Abstract][Full Text] [Related]
13. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
Wilson EM; Kattakuzhy S; Sidharthan S; Sims Z; Tang L; McLaughlin M; Price A; Nelson A; Silk R; Gross C; Akoth E; Mo H; Subramanian GM; Pang PS; McHutchison JG; Osinusi A; Masur H; Kohli A; Kottilil S
Clin Infect Dis; 2016 Feb; 62(3):280-288. PubMed ID: 26521268
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
[TBL] [Abstract][Full Text] [Related]
15. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Yu ML
J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
[TBL] [Abstract][Full Text] [Related]
17. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].
Park SH
Korean J Gastroenterol; 2016 Mar; 67(3):127-31. PubMed ID: 26996181
[TBL] [Abstract][Full Text] [Related]
18. New approaches in the treatment of hepatitis C.
González-Grande R; Jiménez-Pérez M; González Arjona C; Mostazo Torres J
World J Gastroenterol; 2016 Jan; 22(4):1421-32. PubMed ID: 26819511
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
20. Revolution in hepatitis C antiviral therapy.
Sadler MD; Lee SS
Br Med Bull; 2015 Mar; 113(1):31-44. PubMed ID: 25680808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]